Published in Curr Pharm Biotechnol on January 01, 2013
Statin-Conferred Enhanced Cellular Resistance against Bacterial Pore-Forming Toxins in Airway Epithelial Cells. Am J Respir Cell Mol Biol (2015) 0.79
Lipidome and transcriptome profiling of pneumolysin intoxication identifies networks involved in statin-conferred protection of airway epithelial cells. Sci Rep (2015) 0.76
Staphylococcus aureus infections. N Engl J Med (1998) 36.39
Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis (2004) 20.99
Membrane vesicles as conveyors of immune responses. Nat Rev Immunol (2009) 14.72
Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA (2005) 7.41
Carcinogenicity of lipid-lowering drugs. JAMA (1996) 7.04
Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo. Blood (2007) 2.92
Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob (2006) 2.55
The pathogenesis of sepsis. Annu Rev Pathol (2011) 2.55
Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database. Crit Care Med (2006) 2.51
Complement: a unique innate immune sensor for danger signals. Mol Immunol (2004) 2.42
HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation (2004) 2.30
Statins enhance formation of phagocyte extracellular traps. Cell Host Microbe (2010) 2.28
Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost (2009) 2.05
Unexpected antimicrobial effect of statins. J Antimicrob Chemother (2007) 2.05
Exosomes and other microvesicles in infection biology: organelles with unanticipated phenotypes. Cell Microbiol (2010) 1.82
Immunological mechanisms underlying the genetic predisposition to severe Staphylococcus aureus infection in the mouse model. Am J Pathol (2008) 1.77
Mechanisms of statin-mediated inhibition of small G-protein function. J Biol Chem (2005) 1.52
Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther (2000) 1.49
Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen. J Clin Invest (1994) 1.37
The harmful role of c5a on innate immunity in sepsis. J Innate Immun (2010) 1.31
Epidemiology of staphylococcal resistance. Clin Infect Dis (2007) 1.16
Statin (cerivastatin) protects mice against sepsis-related death via reduced proinflammatory cytokines and enhanced bacterial clearance. Surg Infect (Larchmt) (2008) 1.10
Simvastatin inhibits Staphylococcus aureus host cell invasion through modulation of isoprenoid intermediates. J Pharmacol Exp Ther (2008) 1.04
Statin inhibition of Fc receptor-mediated phagocytosis by macrophages is modulated by cell activation and cholesterol. Arterioscler Thromb Vasc Biol (2004) 1.01
Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin. Arterioscler Thromb Vasc Biol (2001) 1.00
Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation. Clin Exp Immunol (2004) 1.00
Opposite effects of simvastatin on the bactericidal and inflammatory response of macrophages to opsonized S. aureus. J Leukoc Biol (2009) 0.91
Simvastatin is protective during Staphylococcus aureus pneumonia. Curr Pharm Biotechnol (2011) 0.89
Simvastatin treatment improves survival in a murine model of burn sepsis: Role of interleukin 6. Burns (2010) 0.88
Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains. Hum Immunol (2005) 0.87
Hydrophobic but not hydrophilic statins enhance phagocytosis and decrease apoptosis of human peripheral blood cells in vitro. Biomed Pharmacother (2007) 0.84
Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis. J Am Soc Nephrol (1998) 0.83
Effect of pravastatin, simvastatin and atorvastatin on the phagocytic activity of mouse peritoneal macrophages. Exp Mol Pathol (2005) 0.82
GTPase activating protein function of p85 facilitates uptake and recycling of the beta1 integrin. Biochem Biophys Res Commun (2009) 0.81
Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia. J Lipid Res (2003) 0.79
Short term effect of atorvastatin and vitamin E on serum levels of C3, a sensitive marker of the risk of myocardial infarction in men. Cardiovasc Drugs Ther (2001) 0.78
Immunomodulator activity of 3-hydroxy-3-methilglutaryl-CoA inhibitors. Cardiovasc Hematol Agents Med Chem (2009) 0.77
HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9. Basic Res Cardiol (2003) 0.77
Statin drugs do not affect serum complement activation in vitro. Scand J Immunol (2004) 0.77
PU.1 expression delineates heterogeneity in primary Th2 cells. Immunity (2005) 1.93
IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice. Hepatology (2014) 1.69
Genetic susceptibility to respiratory syncytial virus infection in inbred mice. J Med Virol (2002) 1.27
The role of metallothionein in the pathogenesis of acute lung injury. Am J Respir Cell Mol Biol (2005) 1.25
IL-4 is a critical determinant in the generation of allergic inflammation initiated by a constitutively active Stat6. J Immunol (2008) 1.12
Kinases as therapeutic targets for heart failure. Nat Rev Drug Discov (2003) 1.09
Th1 cells regulate hematopoietic progenitor cell homeostasis by production of oncostatin M. Immunity (2002) 1.08
Simvastatin inhibits Staphylococcus aureus host cell invasion through modulation of isoprenoid intermediates. J Pharmacol Exp Ther (2008) 1.04
Gene expression profiles of Mst1r-deficient mice during nickel-induced acute lung injury. Am J Respir Cell Mol Biol (2005) 1.03
Acute lung injury: functional genomics and genetic susceptibility. Chest (2002) 1.00
IL-4-stimulated NF-kappaB activity is required for Stat6 DNA binding. J Leukoc Biol (2007) 0.94
Constitutively active STAT6 predisposes toward a lymphoproliferative disorder. Blood (2007) 0.90
Genetic susceptibility to nickel-induced acute lung injury. Chemosphere (2003) 0.89
Differential colonization with segmented filamentous bacteria and Lactobacillus murinus do not drive divergent development of diet-induced obesity in C57BL/6 mice. Mol Metab (2013) 0.89
Wheezing and itching: The requirement for STAT proteins in allergic inflammation. JAKSTAT (2012) 0.84
GTPase activating protein function of p85 facilitates uptake and recycling of the beta1 integrin. Biochem Biophys Res Commun (2009) 0.81
Small Molecule Inhibitors Limit Endothelial Cell Invasion by Staphylococcus aureus. Curr Pharm Biotechnol (2014) 0.78
Host cell invasion by Staphylococcus aureus stimulates the shedding of microvesicles. Biochem Biophys Res Commun (2013) 0.75
Erythromycin treatment hinders the induction of oral tolerance to fed ovalbumin. Front Immunol (2012) 0.75
Active immune response protects Stat6VT transgenic mice from developing a lymphoproliferative disorder. Immunobiology (2009) 0.75
Hemostatic factors as druggable targets in diverse pathologies. Curr Pharm Biotechnol (2011) 0.75
Enumeration of sublethally injured Escherichia coli O157:H7 ATCC 43895 and Escherichia coli strain B-41560 using selective agar overlays versus commercial methods. J Food Prot (2013) 0.75
Short Term, Low Dose Simvastatin Pretreatment Alters Memory Immune Function Following Secondary Staphylococcus aureus Infection. Curr Pharm Biotechnol (2016) 0.75
Erratum: Thermoneutral housing exacerbates nonalcoholic fatty liver disease in mice and allows for sex-independent disease modeling. Nat Med (2017) 0.75